J Lakritz, W D Wilson, A E Marsh, J E Mihalyi
Index: Am. J. Vet. Res. 61(8) , 914-9, (2000)
Full Text: HTML
To determine pharmacokinetics and plasma concentrations of erythromycin and related compounds after intragastric administration of erythromycin phosphate and erythromycin estolate to healthy foals.11 healthy 2- to 6-month-old foals.Food was withheld from foals overnight before intragastric administration of erythromycin estolate (25 mg/kg of body weight; n = 8) and erythromycin phosphate (25 mg/kg; 7). Four foals received both drugs with 2 weeks between treatments. Plasma erythromycin concentrations were determined at various times after drug administration by use of high-performance liquid chromatography. Maximum plasma peak concentrations, time to maximum concentrations, area under plasma concentration versus time curves, half-life of elimination, and mean residence times were determined from concentration versus time curves.Maximum peak concentration of erythromycin A after administration of erythromycin phosphate was significantly greater than after administration of erythromycin estolate (2.9 +/- 1.1 microg/ml vs 1.0 +/- 0.82 microg/ml). Time to maximum concentration was shorter after administration of erythromycin phosphate than after erythromycin estolate (0.71 +/- 0.29 hours vs 1.7 +/- 1.2 hours). Concentrations of anhydroerythromycin A were significantly less 1 and 3 hours after administration of erythromycin estolate than after administration of erythromycin phosphate.Plasma concentrations of erythromycin A remained > 0.25 microg/ml (reported minimum inhibitory concentration for Rhodococcus equi) for at least 4 hours after intragastric administration of erythromycin phosphate or erythromycin estolate, suggesting that the recommended dosage for either formulation (25 mg/kg, q 6 h) should be adequate for treatment of R equi infections in foals.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
Erythromycin Estolate
CAS:3521-62-8 |
C52H97NO18S |
Protective effect of Livex, a herbal formulation against ery...
1998-01-01 [J. Ethnopharmacol. 57(3) , 161-7, (1997)] |
Preparation and characterization of biodegradable poly(l-lac...
2004-03-15 [J. Colloid. Interface Sci. 271(2) , 336-41, (2004)] |
Five days of erythromycin estolate versus ten days of penici...
1996-09-01 [Eur. J. Clin. Microbiol. Infect. Dis. 15(9) , 712-7, (1996)] |
Pharmacokinetics of erythromycin after the administration of...
2008-12-01 [J. Vet. Pharmacol. Ther. 31(6) , 496-500, (2008)] |
Multicenter, randomized, double-blind comparison of erythrom...
1998-07-01 [Eur. J. Clin. Microbiol. Infect. Dis. 17(7) , 470-8, (1998)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved